| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Neoplasms | 47 | 2018 | 589 | 6.200 |
Why?
|
| Colorectal Neoplasms | 38 | 2024 | 1071 | 5.660 |
Why?
|
| Adenoma | 21 | 2024 | 260 | 3.220 |
Why?
|
| Early Detection of Cancer | 20 | 2024 | 487 | 3.150 |
Why?
|
| Spectrum Analysis | 23 | 2018 | 121 | 2.850 |
Why?
|
| Carcinogenesis | 14 | 2024 | 237 | 2.700 |
Why?
|
| Colon | 26 | 2018 | 541 | 2.690 |
Why?
|
| Intestinal Mucosa | 28 | 2018 | 825 | 2.500 |
Why?
|
| Colonoscopy | 16 | 2024 | 304 | 2.330 |
Why?
|
| Polyethylene Glycols | 9 | 2018 | 377 | 2.190 |
Why?
|
| Cell Transformation, Neoplastic | 15 | 2017 | 468 | 2.150 |
Why?
|
| Biomarkers, Tumor | 21 | 2018 | 1662 | 1.780 |
Why?
|
| Precancerous Conditions | 11 | 2017 | 206 | 1.590 |
Why?
|
| Rectum | 9 | 2018 | 151 | 1.550 |
Why?
|
| Mass Screening | 12 | 2013 | 712 | 1.530 |
Why?
|
| Mouth Mucosa | 5 | 2014 | 71 | 1.480 |
Why?
|
| Colonic Polyps | 8 | 2017 | 137 | 1.440 |
Why?
|
| Down-Regulation | 9 | 2018 | 527 | 1.230 |
Why?
|
| Chromatin | 12 | 2024 | 446 | 1.210 |
Why?
|
| Anticarcinogenic Agents | 7 | 2018 | 71 | 1.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2015 | 250 | 1.090 |
Why?
|
| Azoxymethane | 19 | 2018 | 84 | 1.070 |
Why?
|
| Rats, Inbred F344 | 22 | 2013 | 155 | 1.070 |
Why?
|
| Rats | 35 | 2017 | 4134 | 1.040 |
Why?
|
| Intestinal Neoplasms | 5 | 2011 | 70 | 0.970 |
Why?
|
| Smoking | 8 | 2014 | 650 | 0.890 |
Why?
|
| Carcinoma | 6 | 2017 | 449 | 0.890 |
Why?
|
| Scattering, Radiation | 17 | 2013 | 121 | 0.860 |
Why?
|
| Nuclear Proteins | 4 | 2018 | 750 | 0.850 |
Why?
|
| Male | 75 | 2020 | 45735 | 0.840 |
Why?
|
| ErbB Receptors | 4 | 2018 | 513 | 0.830 |
Why?
|
| Humans | 117 | 2024 | 95971 | 0.830 |
Why?
|
| MicroRNAs | 6 | 2018 | 591 | 0.780 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 4 | 2015 | 50 | 0.770 |
Why?
|
| Light | 15 | 2013 | 297 | 0.750 |
Why?
|
| Lung Neoplasms | 5 | 2023 | 2464 | 0.720 |
Why?
|
| Chemoprevention | 5 | 2018 | 93 | 0.710 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2012 | 115 | 0.710 |
Why?
|
| Adenocarcinoma | 8 | 2016 | 1208 | 0.680 |
Why?
|
| Fiber Optic Technology | 3 | 2015 | 36 | 0.640 |
Why?
|
| Endoscopy, Gastrointestinal | 3 | 2012 | 161 | 0.630 |
Why?
|
| Cell Proliferation | 10 | 2014 | 1760 | 0.620 |
Why?
|
| Aspirin | 3 | 2017 | 169 | 0.610 |
Why?
|
| Animals | 55 | 2018 | 28924 | 0.600 |
Why?
|
| Butanones | 3 | 2005 | 8 | 0.580 |
Why?
|
| Transcription Factors | 5 | 2008 | 1731 | 0.580 |
Why?
|
| Prostatic Neoplasms | 5 | 2015 | 1795 | 0.580 |
Why?
|
| Apoptosis | 7 | 2014 | 1760 | 0.580 |
Why?
|
| Aberrant Crypt Foci | 1 | 2018 | 7 | 0.570 |
Why?
|
| Laxatives | 1 | 2018 | 13 | 0.560 |
Why?
|
| Cytokines | 3 | 2020 | 873 | 0.560 |
Why?
|
| Middle Aged | 39 | 2020 | 28255 | 0.560 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 65 | 0.540 |
Why?
|
| Exercise Therapy | 1 | 2018 | 94 | 0.530 |
Why?
|
| Female | 45 | 2020 | 49938 | 0.520 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2012 | 79 | 0.500 |
Why?
|
| Aged | 32 | 2020 | 20877 | 0.490 |
Why?
|
| Sigmoidoscopy | 3 | 2010 | 38 | 0.480 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2018 | 426 | 0.470 |
Why?
|
| HT29 Cells | 10 | 2017 | 50 | 0.470 |
Why?
|
| Case-Control Studies | 10 | 2018 | 1957 | 0.470 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2008 | 303 | 0.460 |
Why?
|
| Carcinogens | 8 | 2012 | 106 | 0.460 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 412 | 0.460 |
Why?
|
| Sensitivity and Specificity | 12 | 2015 | 2040 | 0.460 |
Why?
|
| Microscopy | 5 | 2018 | 91 | 0.450 |
Why?
|
| Risk Factors | 20 | 2017 | 5949 | 0.450 |
Why?
|
| Biopsy | 4 | 2015 | 1221 | 0.450 |
Why?
|
| Precision Medicine | 2 | 2018 | 451 | 0.440 |
Why?
|
| Epithelial Cells | 7 | 2013 | 711 | 0.440 |
Why?
|
| Fatty Acid Synthases | 1 | 2014 | 9 | 0.440 |
Why?
|
| Disease Models, Animal | 15 | 2018 | 2542 | 0.430 |
Why?
|
| Microvessels | 2 | 2014 | 74 | 0.420 |
Why?
|
| Health Status Disparities | 1 | 2017 | 221 | 0.420 |
Why?
|
| Pancreatic Neoplasms | 7 | 2015 | 725 | 0.420 |
Why?
|
| Nanotechnology | 3 | 2013 | 73 | 0.420 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 2012 | 45 | 0.410 |
Why?
|
| Liver Neoplasms | 2 | 2018 | 793 | 0.410 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 1173 | 0.400 |
Why?
|
| Blotting, Western | 7 | 2012 | 798 | 0.400 |
Why?
|
| Health Communication | 1 | 2013 | 14 | 0.390 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 3 | 2013 | 36 | 0.390 |
Why?
|
| Financing, Organized | 1 | 2012 | 13 | 0.390 |
Why?
|
| Peer Review, Research | 1 | 2012 | 37 | 0.380 |
Why?
|
| Pyrazoles | 2 | 2011 | 161 | 0.380 |
Why?
|
| DNA Glycosylases | 1 | 2012 | 25 | 0.380 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2012 | 42 | 0.380 |
Why?
|
| Epidermal Growth Factor | 1 | 2012 | 116 | 0.370 |
Why?
|
| Research Support as Topic | 1 | 2012 | 92 | 0.370 |
Why?
|
| Research Personnel | 1 | 2012 | 84 | 0.360 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2012 | 137 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2020 | 1351 | 0.360 |
Why?
|
| Prostate | 1 | 2015 | 422 | 0.350 |
Why?
|
| Population Surveillance | 1 | 2012 | 218 | 0.350 |
Why?
|
| Sulfonamides | 2 | 2011 | 338 | 0.350 |
Why?
|
| Obesity | 2 | 2017 | 1038 | 0.350 |
Why?
|
| Neoplasms | 7 | 2016 | 3246 | 0.340 |
Why?
|
| S Phase | 1 | 2010 | 64 | 0.340 |
Why?
|
| G1 Phase | 1 | 2010 | 66 | 0.340 |
Why?
|
| Immunohistochemistry | 8 | 2017 | 1829 | 0.340 |
Why?
|
| Predictive Value of Tests | 7 | 2015 | 1805 | 0.330 |
Why?
|
| Mouth Neoplasms | 1 | 2012 | 202 | 0.320 |
Why?
|
| Sex Factors | 7 | 2012 | 1132 | 0.320 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 589 | 0.320 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 296 | 0.320 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 305 | 0.320 |
Why?
|
| Up-Regulation | 5 | 2017 | 741 | 0.310 |
Why?
|
| Refractometry | 5 | 2012 | 10 | 0.310 |
Why?
|
| Mice | 21 | 2018 | 12559 | 0.310 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 2494 | 0.310 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 357 | 0.310 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 381 | 0.310 |
Why?
|
| Alcohol Drinking | 3 | 2009 | 287 | 0.310 |
Why?
|
| Fractals | 3 | 2017 | 42 | 0.300 |
Why?
|
| Surface-Active Agents | 2 | 2010 | 63 | 0.300 |
Why?
|
| Duodenum | 4 | 2015 | 112 | 0.300 |
Why?
|
| Stem Cells | 1 | 2011 | 394 | 0.290 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 1269 | 0.290 |
Why?
|
| Sulindac | 1 | 2008 | 8 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 2473 | 0.290 |
Why?
|
| Tomography, Optical Coherence | 4 | 2014 | 133 | 0.290 |
Why?
|
| Medical Oncology | 2 | 2011 | 407 | 0.290 |
Why?
|
| Cathartics | 1 | 2008 | 27 | 0.280 |
Why?
|
| Reproducibility of Results | 9 | 2015 | 2876 | 0.270 |
Why?
|
| beta Catenin | 2 | 2006 | 267 | 0.270 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2007 | 88 | 0.270 |
Why?
|
| Phosphates | 1 | 2008 | 167 | 0.260 |
Why?
|
| Pilot Projects | 5 | 2018 | 936 | 0.260 |
Why?
|
| Aged, 80 and over | 11 | 2019 | 7205 | 0.250 |
Why?
|
| Fuzzy Logic | 1 | 2006 | 16 | 0.250 |
Why?
|
| Mutation | 6 | 2015 | 4371 | 0.250 |
Why?
|
| Snail Family Transcription Factors | 4 | 2008 | 48 | 0.250 |
Why?
|
| Human Genome Project | 1 | 2005 | 22 | 0.240 |
Why?
|
| Clinical Medicine | 1 | 2005 | 34 | 0.240 |
Why?
|
| Genetics | 1 | 2005 | 24 | 0.230 |
Why?
|
| Neoplasm Proteins | 4 | 2014 | 554 | 0.230 |
Why?
|
| Diagnostic Imaging | 5 | 2012 | 473 | 0.230 |
Why?
|
| Cell Line, Tumor | 7 | 2020 | 2785 | 0.230 |
Why?
|
| Incidence | 6 | 2016 | 1705 | 0.230 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2005 | 158 | 0.220 |
Why?
|
| Genes, APC | 1 | 2004 | 27 | 0.220 |
Why?
|
| Adult | 18 | 2018 | 28637 | 0.220 |
Why?
|
| Neoplasm Staging | 6 | 2015 | 2082 | 0.220 |
Why?
|
| Double-Blind Method | 3 | 2018 | 1794 | 0.220 |
Why?
|
| Hemoglobins | 6 | 2018 | 196 | 0.220 |
Why?
|
| Risk Assessment | 6 | 2018 | 2478 | 0.210 |
Why?
|
| Optics and Photonics | 5 | 2013 | 26 | 0.210 |
Why?
|
| Cyclin D1 | 3 | 2012 | 85 | 0.210 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 227 | 0.210 |
Why?
|
| Disease Progression | 6 | 2018 | 1567 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 1461 | 0.200 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 2420 | 0.200 |
Why?
|
| Necrobiotic Disorders | 1 | 2003 | 1 | 0.200 |
Why?
|
| Mice, Mutant Strains | 4 | 2006 | 232 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 6 | 2008 | 1050 | 0.190 |
Why?
|
| Protein Kinase C | 5 | 1995 | 267 | 0.190 |
Why?
|
| Mucin-4 | 2 | 2015 | 7 | 0.190 |
Why?
|
| Kidney | 1 | 2008 | 1156 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 7 | 2015 | 3489 | 0.190 |
Why?
|
| Signal Transduction | 5 | 2010 | 3587 | 0.190 |
Why?
|
| Artificial Intelligence | 2 | 2024 | 400 | 0.190 |
Why?
|
| Trans-Activators | 1 | 2005 | 448 | 0.190 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2012 | 37 | 0.180 |
Why?
|
| src-Family Kinases | 4 | 2010 | 70 | 0.180 |
Why?
|
| Genes, bcl-2 | 1 | 2001 | 15 | 0.180 |
Why?
|
| Abnormalities, Multiple | 1 | 2002 | 238 | 0.170 |
Why?
|
| Transcription, Genetic | 3 | 2020 | 1192 | 0.170 |
Why?
|
| Feces | 2 | 2013 | 360 | 0.170 |
Why?
|
| Forkhead Transcription Factors | 2 | 2013 | 180 | 0.170 |
Why?
|
| Occult Blood | 2 | 2013 | 28 | 0.170 |
Why?
|
| Lung Diseases | 1 | 2003 | 290 | 0.170 |
Why?
|
| Endoscopy, Digestive System | 4 | 2014 | 72 | 0.170 |
Why?
|
| Optical Fibers | 2 | 2018 | 3 | 0.160 |
Why?
|
| Adaptation, Physiological | 2 | 2020 | 340 | 0.160 |
Why?
|
| HCT116 Cells | 2 | 2018 | 164 | 0.160 |
Why?
|
| Cell Cycle | 3 | 2012 | 518 | 0.160 |
Why?
|
| Ethanol | 1 | 2002 | 270 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2005 | 649 | 0.160 |
Why?
|
| Cadherins | 3 | 2006 | 180 | 0.160 |
Why?
|
| Guideline Adherence | 1 | 2001 | 244 | 0.160 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1999 | 107 | 0.150 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 1618 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2001 | 396 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 898 | 0.150 |
Why?
|
| Time Factors | 8 | 2017 | 5577 | 0.150 |
Why?
|
| Celecoxib | 2 | 2011 | 33 | 0.150 |
Why?
|
| Genital Neoplasms, Female | 1 | 1999 | 114 | 0.140 |
Why?
|
| Veterans Health | 1 | 2018 | 19 | 0.140 |
Why?
|
| Vitamin D | 1 | 2020 | 273 | 0.140 |
Why?
|
| Prognosis | 5 | 2018 | 4024 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 684 | 0.140 |
Why?
|
| Sex Distribution | 2 | 2010 | 174 | 0.140 |
Why?
|
| Placebo Effect | 1 | 2018 | 35 | 0.140 |
Why?
|
| Age Factors | 5 | 2012 | 1963 | 0.140 |
Why?
|
| Optical Imaging | 1 | 2018 | 51 | 0.140 |
Why?
|
| Internal Medicine | 1 | 2001 | 371 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 185 | 0.130 |
Why?
|
| Isoenzymes | 5 | 2001 | 278 | 0.130 |
Why?
|
| Glutaredoxins | 1 | 2017 | 1 | 0.130 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2017 | 12 | 0.130 |
Why?
|
| Ampulla of Vater | 2 | 2014 | 25 | 0.130 |
Why?
|
| Binding Sites | 2 | 2018 | 1167 | 0.130 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2017 | 14 | 0.130 |
Why?
|
| Models, Biological | 4 | 2020 | 1814 | 0.130 |
Why?
|
| Mucins | 1 | 2017 | 40 | 0.130 |
Why?
|
| Penetrance | 1 | 2017 | 48 | 0.130 |
Why?
|
| Muscle Contraction | 1 | 2018 | 294 | 0.130 |
Why?
|
| Sirtuin 1 | 1 | 2017 | 37 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 246 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2001 | 570 | 0.130 |
Why?
|
| Carrier Proteins | 3 | 2006 | 684 | 0.130 |
Why?
|
| Algorithms | 4 | 2019 | 2011 | 0.130 |
Why?
|
| Phantoms, Imaging | 5 | 2018 | 488 | 0.130 |
Why?
|
| Nanostructures | 2 | 2014 | 89 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2018 | 283 | 0.120 |
Why?
|
| Crohn Disease | 1 | 2003 | 806 | 0.120 |
Why?
|
| Cytoskeleton | 3 | 2014 | 200 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 298 | 0.120 |
Why?
|
| Hyperplasia | 2 | 2014 | 149 | 0.120 |
Why?
|
| Fatty Liver | 1 | 2017 | 108 | 0.120 |
Why?
|
| Lipid Metabolism | 2 | 2017 | 221 | 0.120 |
Why?
|
| Molecular Imaging | 1 | 2016 | 72 | 0.120 |
Why?
|
| Dinoprostone | 1 | 2015 | 74 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2017 | 109 | 0.120 |
Why?
|
| Spectrophotometry | 3 | 2013 | 108 | 0.120 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2006 | 36 | 0.120 |
Why?
|
| Duodenoscopy | 1 | 2015 | 9 | 0.120 |
Why?
|
| Piroxicam | 1 | 1995 | 11 | 0.120 |
Why?
|
| Stomach Neoplasms | 2 | 2008 | 310 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2017 | 4663 | 0.120 |
Why?
|
| United States | 7 | 2011 | 7762 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 346 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 334 | 0.110 |
Why?
|
| Mucous Membrane | 2 | 2008 | 85 | 0.110 |
Why?
|
| Medical Overuse | 1 | 2015 | 40 | 0.110 |
Why?
|
| RNA, Messenger | 2 | 2011 | 2092 | 0.110 |
Why?
|
| Equipment Design | 4 | 2015 | 427 | 0.110 |
Why?
|
| Calcitriol | 4 | 1997 | 173 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2012 | 690 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2012 | 340 | 0.110 |
Why?
|
| Glucuronosyltransferase | 1 | 2015 | 186 | 0.110 |
Why?
|
| Caspase 3 | 2 | 2004 | 164 | 0.110 |
Why?
|
| Caspases | 2 | 2004 | 156 | 0.110 |
Why?
|
| Inflammation | 1 | 2020 | 1069 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 321 | 0.110 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 156 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2006 | 307 | 0.100 |
Why?
|
| Biomarkers | 2 | 2024 | 1933 | 0.100 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2014 | 82 | 0.100 |
Why?
|
| Image Enhancement | 2 | 2009 | 565 | 0.100 |
Why?
|
| Transcriptome | 2 | 2017 | 771 | 0.100 |
Why?
|
| Ribulose-Bisphosphate Carboxylase | 1 | 1993 | 11 | 0.100 |
Why?
|
| Intestines | 2 | 2009 | 430 | 0.100 |
Why?
|
| Ovarian Neoplasms | 2 | 2013 | 828 | 0.100 |
Why?
|
| Microcirculation | 3 | 2009 | 109 | 0.100 |
Why?
|
| Enzyme Induction | 2 | 2008 | 87 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 403 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2014 | 3093 | 0.100 |
Why?
|
| Endometrium | 1 | 2013 | 52 | 0.100 |
Why?
|
| Cervix Uteri | 1 | 2013 | 73 | 0.100 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2014 | 187 | 0.100 |
Why?
|
| Microscopy, Electron | 2 | 2011 | 510 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 2059 | 0.100 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2012 | 15 | 0.100 |
Why?
|
| Histone Deacetylases | 1 | 2013 | 86 | 0.100 |
Why?
|
| Colitis | 1 | 2015 | 262 | 0.100 |
Why?
|
| Administration, Topical | 1 | 2012 | 96 | 0.090 |
Why?
|
| Cataract | 1 | 1993 | 87 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2001 | 1121 | 0.090 |
Why?
|
| Legislation as Topic | 1 | 2011 | 3 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2014 | 339 | 0.090 |
Why?
|
| Endoscopy | 2 | 2013 | 374 | 0.090 |
Why?
|
| Citrobacter rodentium | 1 | 2011 | 14 | 0.090 |
Why?
|
| Colitis, Microscopic | 1 | 2011 | 6 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2012 | 176 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2018 | 1324 | 0.090 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2011 | 25 | 0.090 |
Why?
|
| Bacterial Adhesion | 1 | 2011 | 85 | 0.090 |
Why?
|
| Optical Phenomena | 1 | 2011 | 8 | 0.090 |
Why?
|
| Colonoscopes | 1 | 2011 | 13 | 0.090 |
Why?
|
| Radiotherapy | 2 | 2012 | 328 | 0.090 |
Why?
|
| Fluorescence | 1 | 2011 | 106 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2019 | 10190 | 0.090 |
Why?
|
| Risk | 2 | 2011 | 669 | 0.080 |
Why?
|
| Genotype | 1 | 2015 | 1882 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2011 | 192 | 0.080 |
Why?
|
| Epithelium | 1 | 2011 | 328 | 0.080 |
Why?
|
| Cell Survival | 3 | 2015 | 1032 | 0.080 |
Why?
|
| Reference Values | 3 | 2008 | 674 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2011 | 326 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 1 | 2010 | 137 | 0.080 |
Why?
|
| Video Recording | 1 | 2011 | 214 | 0.080 |
Why?
|
| Carcinogenicity Tests | 1 | 2009 | 5 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 1875 | 0.080 |
Why?
|
| Dietary Fats | 2 | 2000 | 137 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 1969 | 0.080 |
Why?
|
| Gastric Mucins | 1 | 2008 | 1 | 0.080 |
Why?
|
| Polyps | 1 | 2009 | 26 | 0.070 |
Why?
|
| Age of Onset | 2 | 2009 | 344 | 0.070 |
Why?
|
| Leprosy | 1 | 2008 | 8 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2008 | 1666 | 0.070 |
Why?
|
| Colectomy | 1 | 2010 | 192 | 0.070 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2009 | 96 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 701 | 0.070 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2008 | 10 | 0.070 |
Why?
|
| Endoscopes, Gastrointestinal | 1 | 2008 | 8 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 1534 | 0.070 |
Why?
|
| Nanoparticles | 1 | 2010 | 197 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 84 | 0.070 |
Why?
|
| Macromolecular Substances | 2 | 2020 | 179 | 0.070 |
Why?
|
| Particle Size | 1 | 2008 | 126 | 0.070 |
Why?
|
| Rectal Neoplasms | 1 | 2009 | 134 | 0.070 |
Why?
|
| CA-125 Antigen | 1 | 2007 | 22 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 395 | 0.070 |
Why?
|
| Lysosomes | 1 | 2008 | 124 | 0.070 |
Why?
|
| Pancreatic Ducts | 1 | 2007 | 30 | 0.070 |
Why?
|
| alpha-Fetoproteins | 1 | 2007 | 46 | 0.070 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2007 | 45 | 0.070 |
Why?
|
| Early Diagnosis | 2 | 2007 | 137 | 0.070 |
Why?
|
| Quinazolines | 1 | 2008 | 216 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2009 | 912 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 248 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 306 | 0.060 |
Why?
|
| Monte Carlo Method | 3 | 2013 | 191 | 0.060 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1995 | 133 | 0.060 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2006 | 34 | 0.060 |
Why?
|
| Gene Knockout Techniques | 2 | 2017 | 85 | 0.060 |
Why?
|
| Ornithine Decarboxylase | 1 | 2006 | 10 | 0.060 |
Why?
|
| Models, Theoretical | 2 | 2008 | 503 | 0.060 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 156 | 0.060 |
Why?
|
| Apigenin | 1 | 2006 | 8 | 0.060 |
Why?
|
| Prevalence | 1 | 2010 | 1345 | 0.060 |
Why?
|
| Radiography | 2 | 2006 | 813 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2005 | 56 | 0.060 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2005 | 15 | 0.060 |
Why?
|
| Age Distribution | 1 | 2006 | 210 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2010 | 367 | 0.060 |
Why?
|
| Veterans | 1 | 2006 | 100 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2005 | 40 | 0.060 |
Why?
|
| Tunica Intima | 1 | 2005 | 61 | 0.060 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2005 | 38 | 0.060 |
Why?
|
| Ursodeoxycholic Acid | 2 | 1995 | 26 | 0.060 |
Why?
|
| Blood Flow Velocity | 1 | 2006 | 202 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 346 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2008 | 447 | 0.060 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 548 | 0.060 |
Why?
|
| Valproic Acid | 2 | 2015 | 25 | 0.060 |
Why?
|
| Morpholinos | 1 | 2004 | 13 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2005 | 71 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 124 | 0.060 |
Why?
|
| Carotid Arteries | 1 | 2005 | 136 | 0.050 |
Why?
|
| Medicine | 1 | 2005 | 99 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2007 | 703 | 0.050 |
Why?
|
| Morpholines | 1 | 2004 | 77 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 656 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2010 | 2163 | 0.050 |
Why?
|
| RNA Interference | 1 | 2005 | 385 | 0.050 |
Why?
|
| Microscopy, Confocal | 2 | 2018 | 287 | 0.050 |
Why?
|
| Cell Division | 2 | 2005 | 705 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2004 | 133 | 0.050 |
Why?
|
| Heterozygote | 1 | 2004 | 382 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2015 | 107 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 1007 | 0.050 |
Why?
|
| Acetaldehyde | 1 | 2002 | 7 | 0.050 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2002 | 11 | 0.050 |
Why?
|
| Malondialdehyde | 1 | 2002 | 26 | 0.050 |
Why?
|
| Water | 1 | 2004 | 307 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2002 | 68 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2002 | 128 | 0.050 |
Why?
|
| Rodentia | 1 | 2002 | 46 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2015 | 819 | 0.050 |
Why?
|
| Logistic Models | 1 | 2006 | 1263 | 0.050 |
Why?
|
| Forkhead Box Protein O3 | 2 | 2013 | 21 | 0.050 |
Why?
|
| Colchicine | 2 | 2013 | 23 | 0.050 |
Why?
|
| Macrophages | 2 | 2005 | 626 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1765 | 0.040 |
Why?
|
| Tetrazolium Salts | 1 | 2001 | 12 | 0.040 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 37 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 2001 | 65 | 0.040 |
Why?
|
| Tissue Array Analysis | 2 | 2014 | 132 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2001 | 65 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 611 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2001 | 100 | 0.040 |
Why?
|
| Adolescent | 3 | 2017 | 9888 | 0.040 |
Why?
|
| Cell Separation | 1 | 2001 | 205 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2005 | 619 | 0.040 |
Why?
|
| Nitrogenous Group Transferases | 1 | 2000 | 1 | 0.040 |
Why?
|
| Oxygen | 1 | 2006 | 787 | 0.040 |
Why?
|
| Registries | 1 | 2006 | 986 | 0.040 |
Why?
|
| Thermus thermophilus | 1 | 2000 | 10 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 125 | 0.040 |
Why?
|
| Thiazoles | 1 | 2001 | 130 | 0.040 |
Why?
|
| RNA, Transfer, Amino Acyl | 1 | 2000 | 10 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2001 | 204 | 0.040 |
Why?
|
| Calcium | 2 | 1995 | 1205 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2001 | 209 | 0.040 |
Why?
|
| Aging | 1 | 2005 | 766 | 0.040 |
Why?
|
| Causality | 1 | 1999 | 82 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 207 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2001 | 727 | 0.040 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2018 | 27 | 0.040 |
Why?
|
| Dextrans | 1 | 2018 | 78 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 363 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2003 | 1006 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2018 | 92 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2018 | 83 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 166 | 0.030 |
Why?
|
| Type C Phospholipases | 1 | 1997 | 27 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2013 | 1277 | 0.030 |
Why?
|
| Acute Disease | 1 | 2019 | 871 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 283 | 0.030 |
Why?
|
| Protective Factors | 1 | 2017 | 28 | 0.030 |
Why?
|
| Prostaglandins | 1 | 2017 | 44 | 0.030 |
Why?
|
| Boston | 1 | 2017 | 39 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 54 | 0.030 |
Why?
|
| Exercise | 1 | 2000 | 354 | 0.030 |
Why?
|
| Glutathione | 1 | 2017 | 106 | 0.030 |
Why?
|
| Acetylation | 1 | 2017 | 149 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2011 | 900 | 0.030 |
Why?
|
| Surveys and Questionnaires | 3 | 2011 | 2863 | 0.030 |
Why?
|
| Cricetulus | 1 | 2016 | 132 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 69 | 0.030 |
Why?
|
| CHO Cells | 1 | 2016 | 196 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2017 | 161 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1536 | 0.030 |
Why?
|
| Organelles | 1 | 2016 | 58 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 163 | 0.030 |
Why?
|
| Tomography, Optical | 1 | 2015 | 9 | 0.030 |
Why?
|
| Phosphorylation | 3 | 2010 | 1157 | 0.030 |
Why?
|
| Histiocytes | 1 | 2015 | 25 | 0.030 |
Why?
|
| Duodenoscopes | 1 | 2015 | 9 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2015 | 136 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2016 | 521 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2015 | 61 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2015 | 64 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2009 | 594 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2015 | 102 | 0.030 |
Why?
|
| Adenosine Triphosphate | 2 | 1993 | 329 | 0.030 |
Why?
|
| Intracellular Membranes | 1 | 1994 | 117 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 880 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2014 | 47 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 138 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1993 | 27 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1993 | 33 | 0.030 |
Why?
|
| Isomerism | 1 | 1993 | 30 | 0.030 |
Why?
|
| Enzyme Stability | 1 | 1993 | 41 | 0.030 |
Why?
|
| Endosonography | 1 | 2014 | 101 | 0.030 |
Why?
|
| Perilipin-2 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Potassium Chloride | 1 | 1993 | 88 | 0.030 |
Why?
|
| Plants, Medicinal | 1 | 1993 | 40 | 0.030 |
Why?
|
| Fabaceae | 1 | 1993 | 25 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 379 | 0.030 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 23 | 0.020 |
Why?
|
| Research Design | 1 | 2017 | 631 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 2755 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 647 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2013 | 205 | 0.020 |
Why?
|
| Jaundice, Obstructive | 1 | 2012 | 11 | 0.020 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2012 | 12 | 0.020 |
Why?
|
| Gallbladder | 1 | 2012 | 33 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 2016 | 537 | 0.020 |
Why?
|
| Electroporation | 1 | 2012 | 57 | 0.020 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2012 | 68 | 0.020 |
Why?
|
| Sirtuins | 1 | 2013 | 80 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 391 | 0.020 |
Why?
|
| Radiology, Interventional | 1 | 2012 | 67 | 0.020 |
Why?
|
| Ablation Techniques | 1 | 2012 | 41 | 0.020 |
Why?
|
| Integrin beta1 | 1 | 2011 | 35 | 0.020 |
Why?
|
| Anthropometry | 1 | 2011 | 78 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 125 | 0.020 |
Why?
|
| Photochemotherapy | 1 | 2012 | 101 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2015 | 564 | 0.020 |
Why?
|
| Postmenopause | 1 | 2011 | 107 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 189 | 0.020 |
Why?
|
| Drainage | 1 | 2012 | 170 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2012 | 127 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 203 | 0.020 |
Why?
|
| Adenine Nucleotides | 1 | 1971 | 63 | 0.020 |
Why?
|
| Cytochalasin D | 1 | 2010 | 15 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 393 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2012 | 271 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2012 | 235 | 0.020 |
Why?
|
| Cytosol | 1 | 2010 | 198 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 855 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2016 | 891 | 0.020 |
Why?
|
| Body Composition | 2 | 2000 | 75 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 992 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 285 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 415 | 0.020 |
Why?
|
| Duodenal Neoplasms | 1 | 2009 | 21 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 98 | 0.020 |
Why?
|
| Gene Expression | 2 | 2008 | 1321 | 0.020 |
Why?
|
| Embolization, Therapeutic | 1 | 2012 | 279 | 0.020 |
Why?
|
| Exercise Test | 2 | 2000 | 178 | 0.020 |
Why?
|
| Ulnar Nerve | 1 | 2008 | 8 | 0.020 |
Why?
|
| Stents | 1 | 2012 | 425 | 0.020 |
Why?
|
| Methods | 1 | 2008 | 149 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2013 | 1158 | 0.020 |
Why?
|
| Median Nerve | 1 | 2008 | 14 | 0.020 |
Why?
|
| Oxidation-Reduction | 2 | 2000 | 411 | 0.020 |
Why?
|
| Calibration | 1 | 2009 | 108 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1997 | 1264 | 0.020 |
Why?
|
| Brazil | 1 | 2008 | 82 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 309 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2009 | 181 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 1317 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 139 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 300 | 0.020 |
Why?
|
| SEER Program | 1 | 2009 | 234 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 2008 | 70 | 0.020 |
Why?
|
| Nervous System | 1 | 2008 | 92 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 280 | 0.020 |
Why?
|
| Diet | 2 | 2006 | 461 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 326 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2010 | 623 | 0.020 |
Why?
|
| Bangladesh | 1 | 2008 | 339 | 0.020 |
Why?
|
| Energy Metabolism | 2 | 2000 | 313 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 1101 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1173 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 907 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 842 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2008 | 280 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2006 | 111 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2009 | 272 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2005 | 2 | 0.020 |
Why?
|
| Lac Operon | 1 | 2005 | 46 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2006 | 125 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2006 | 86 | 0.010 |
Why?
|
| Elasticity | 1 | 2006 | 104 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2005 | 49 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 297 | 0.010 |
Why?
|
| Capillaries | 1 | 2005 | 86 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2005 | 86 | 0.010 |
Why?
|
| Random Allocation | 1 | 2006 | 332 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2005 | 156 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2012 | 1201 | 0.010 |
Why?
|
| Cell Movement | 1 | 2008 | 820 | 0.010 |
Why?
|
| Lighting | 1 | 2004 | 34 | 0.010 |
Why?
|
| Rabbits | 1 | 2005 | 649 | 0.010 |
Why?
|
| Enzyme Activation | 2 | 1997 | 692 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 590 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 7001 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 408 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2017 | 9092 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1981 | 0.010 |
Why?
|
| Kinetics | 2 | 1995 | 1562 | 0.010 |
Why?
|
| Protein Structure, Quaternary | 1 | 2000 | 103 | 0.010 |
Why?
|
| Rest | 1 | 2000 | 53 | 0.010 |
Why?
|
| Basal Metabolism | 1 | 2000 | 19 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2000 | 162 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 2000 | 39 | 0.010 |
Why?
|
| RNA, Bacterial | 1 | 2000 | 112 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 1995 | 2943 | 0.010 |
Why?
|
| Energy Intake | 1 | 2000 | 100 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 2000 | 199 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2000 | 213 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2000 | 368 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2000 | 397 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 648 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2000 | 257 | 0.010 |
Why?
|
| Respiration | 1 | 2000 | 281 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2000 | 1028 | 0.010 |
Why?
|
| Phosphatidylinositol Diacylglycerol-Lyase | 1 | 1997 | 7 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2000 | 269 | 0.010 |
Why?
|
| Phospholipase C gamma | 1 | 1997 | 14 | 0.010 |
Why?
|
| Phosphoinositide Phospholipase C | 1 | 1997 | 6 | 0.010 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 1997 | 25 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2000 | 627 | 0.010 |
Why?
|
| Child | 1 | 2008 | 7624 | 0.010 |
Why?
|
| Tyrosine | 1 | 1997 | 132 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 2093 | 0.010 |
Why?
|
| Cholic Acids | 1 | 1995 | 7 | 0.010 |
Why?
|
| Cholic Acid | 1 | 1995 | 8 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 3041 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1997 | 1010 | 0.010 |
Why?
|
| Isoelectric Point | 1 | 1995 | 14 | 0.010 |
Why?
|
| Okadaic Acid | 1 | 1995 | 10 | 0.010 |
Why?
|
| Ethers, Cyclic | 1 | 1995 | 8 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1995 | 156 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1995 | 58 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1995 | 332 | 0.010 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 1994 | 28 | 0.010 |
Why?
|
| Insulin | 1 | 2000 | 1190 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1994 | 181 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1994 | 296 | 0.010 |
Why?
|
| Vitamin D Deficiency | 1 | 1995 | 107 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1971 | 112 | 0.010 |
Why?
|
| Carbon Isotopes | 1 | 1971 | 76 | 0.010 |
Why?
|
| Chloroplasts | 1 | 1971 | 69 | 0.010 |
Why?
|